CALT Overview
Upcoming Projects (CALT)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (CALT)
-
Quarterly Survey: TVTX's Filspari (sparsentan) and CALT's Tarpeyo (budesonide) in treating IgAN October 2024
Tickers: TVTX, CALT
Executed On: Nov 01, 2024 at 01:46 PM EDT -
Discussing the data from the Phase 2b TRANSFORM tria of Calliditas' setanaxib, a NOX enzyme inhibitor in treating primary biliary cholangitis
Ticker: CALT
Executed On: Aug 05, 2024 at 09:00 AM EDT -
Quarterly Survey: TVTX's Filspari (sparsentan) and CALT's Tarpeyo (budesonide) in treating IgAN July 2024
Tickers: TVTX, CALT
Executed On: Jul 26, 2024 at 12:42 PM EDT -
Quarterly Survey: TVTX's Filspari (sparsentan) and CALT's Tarpeyo (budesonide) in treating IgAN April 2024
Tickers: TVTX, CALT
Executed On: Apr 18, 2024 at 04:41 PM EDT -
Quarterly Survey: TVTX's Filspari (sparsentan) and CALT's Tarpeyo (budesonide) in treating IgAN January 2024
Tickers: TVTX, CALT
Executed On: Jan 23, 2024 at 03:55 PM EST -
Delving into the recent phase 3 data from the ALIGN clinical trial of Novartis' atrasentan in patients with IgA Nephropathy.
Tickers: NVS, TVTX, CALT, KDNY
Executed On: Nov 17, 2023 at 09:00 AM EST -
Quarterly Survey: TVTX's Filspari (sparsentan) and CALT's Tarpeyo (budesonide) in treating IgAN October 2023
Tickers: TVTX, CALT
Executed On: Oct 30, 2023 at 05:25 PM EDT -
A Third Opinion: Digging into the IgAN landscape with a focus on Travere's Filspari (sparsentan), Calliditas' Nefecon (Tarpeyo/Kinpeygo), and Chinook's Atrasentan
Tickers: CALT, NVS, TVTX, KDNY
Executed On: Jun 13, 2023 at 04:00 PM EDT -
A Second Opinion: Digging into the IgAN landscape with a focus on Travere's Filspari (sparsentan), Calliditas' Nefecon (Tarpeyo/Kinpeygo), and Chinook's Atrasentan
Tickers: CALT, TVTX, KDNY
Executed On: Jun 06, 2023 at 09:00 AM EDT -
Digging into the IgAN landscape with a focus on Travere's Filspari (sparsentan), Calliditas' Nefecon (Tarpeyo/Kinpeygo), and Chinook's Atrasentan
Tickers: CALT, TVTX, KDNY
Executed On: Jun 01, 2023 at 11:30 AM EDT -
Quarterly Survey: TVTX's Filspari (sparsentan) and CALT's Tarpeyo (budesonide) in treating IgAN
Tickers: TVTX, CALT
Executed On: May 22, 2023 at 04:44 PM EDT -
Delving into the NefIgArd phase 3 data on Nefecon, Calliditas' formulation of budesonide for the treatment of IgA Nephropathy
Ticker: CALT
Executed On: Apr 20, 2023 at 09:45 AM EDT -
A look at the recent approval of Tarpeyo and a view on commercial potential
Ticker: CALT
Executed On: May 03, 2022 at 11:00 AM EDT
Upcoming & Overdue Catalysts (CALT)
-
Don’t see a catalyst related to the company you care about? Create your own!
Occurred Catalysts (CALT)
-
Calliditas (CALT) Announces Topline Results from Pivotal Phase 3 NefIgArd Trial in IgA nephropathy
Ticker: CALT
Occurred on: Nov 08, 2020
Strategic Initiatives (CALT)
-
Don’t see a strategic initiative related to the company you care about? Create your own!
